{"id":59339,"date":"2024-02-28T05:53:18","date_gmt":"2024-02-28T05:53:18","guid":{"rendered":"https:\/\/medsname.com\/silectone\/"},"modified":"2026-05-01T10:49:15","modified_gmt":"2026-05-01T10:49:15","slug":"silectone","status":"publish","type":"product","link":"https:\/\/medsbase.com\/sv\/product\/silectone\/","title":{"rendered":"Silectone"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Silectone?<\/h3>\n

Silectone<\/strong> \u00e4r en 25 \/ 50 mg spironolactone tablet<\/strong> fr\u00e5n Sun Pharma \u2014 ett mineralocorticoid receptor antagonist (aldosterone antagonist)<\/strong> som verkar p\u00e5 mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone. Half-life 1.4 hours (parent); 16-24 hours (active metabolites canrenone and 7-\u03b1-thiomethylspirolactone); onset 24-48 hours (needs time for receptor antagonism to manifest at the tissue level); peak effect 2-3 days; duration 2-3 days after discontinuation. Primary indication: heart failure with reduced ejection fraction (HF-REF), primary aldosteronism, resistant hypertension, cirrhotic ascites, adjunct treatment for hirsutism and PCOS<\/strong>. Vanlig dosering: Resistent hypertoni<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Inte ett f\u00f6rstahandsval vid hypertoni.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg. Key contraindications: see full list below. Monitor electrolytes, creatinine, and glucose. Kombinera inte med litium<\/strong> (tiazid-\/loopdiuretika kan framkalla litiumtoxicitet). Anv\u00e4ndning under graviditet bed\u00f6ms individuellt<\/strong> (se graviditetsanteckning). F\u00f6r de flesta hypertonipatienter fungerar diuretika b\u00e4st som andra eller tredje behandlingsalternativ<\/strong> \u2014 vanligen i kombination med en ARB, ACE-h\u00e4mmare eller kalciumkanalblockerare snarare \u00e4n som monoterapi.<\/p>\n<\/div>\n

\nVad du f\u00e5r med MedsBase:<\/strong> WHO-GMP-certifierad tillverkare \u00b7 Diskret f\u00f6rpackning \u00b7 V\u00e4rldsvid leverans \u00b7 1 400+ verifierade kundrecensioner<\/a>\n<\/div>\n

\ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n

Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n

V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n

What Is Silectone?<\/h2>\n

Silectone is an oral 25 \/ 50 mg spironolactone tablet from Sun Pharma, supplied in 30-180 tablets. Spironolactone was introduced by G.D. Searle in 1959 — designed as a synthetic steroid to antagonise aldosterone’s distal-tubule effect on sodium retention and potassium excretion. The first MR antagonist; remains the reference agent despite the availability of the more selective eplerenone.<\/p>\n

How Spironolactone Works<\/h2>\n

Spironolactone inhibits the mineralocorticoid receptor (MR) in the principal cells of the cortical collecting duct<\/strong>. De nedstr\u00f6ms effekterna:<\/p>\n

    \n
  • Blocks aldosterone at the mineralocorticoid receptor<\/strong> in principal cells of the cortical collecting duct<\/li>\n
  • Reduced sodium reabsorption, reduced potassium secretion<\/strong> \u2014 mild natriures med kaliumkvarh\u00e5llande (kaliumsparande)<\/li>\n
  • Anti-fibrotic and anti-remodelling effect in myocardium<\/strong> — aldosterone drives cardiac fibrosis independent of its salt-retaining effect; blocking the receptor reduces fibrosis. This is the main mechanism of the HF-REF mortality benefit (RALES).<\/li>\n
  • Anti-androgen activity<\/strong> — cross-reactivity with androgen and progesterone receptors produces gynaecomastia and menstrual irregularity as class side effects; same activity gives its off-label role in hirsutism and PCOS.<\/li>\n
  • Delayed onset\/offset<\/strong> (24-72 hours each direction) — receptor pharmacology plus long-acting active metabolites (canrenone)<\/li>\n
  • Effective at resistant hypertension<\/strong> (PATHWAY-2) — acts on the subpopulation of hypertensives with covert aldosterone excess<\/li>\n<\/ul>\n

    Godk\u00e4nda och evidensbaserade anv\u00e4ndningsomr\u00e5den<\/h2>\n
      \n
    • Heart failure with reduced ejection fraction (HF-REF), primary aldosteronism, resistant hypertension, cirrhotic ascites, adjunct treatment for hirsutism and PCOS<\/strong> \u2014 prim\u00e4r indikation<\/li>\n
    • Heart failure with reduced ejection fraction (EF ≤35%)<\/strong> — RALES evidence, 25-50 mg daily<\/li>\n
    • Primary aldosteronism (Conn’s syndrome)<\/strong> — definitive medical therapy for bilateral adrenal hyperplasia; bridging therapy for unilateral adenoma pre-surgery<\/li>\n
    • Resistent hypertoni<\/strong> — PATHWAY-2 evidence; fourth-line agent after ACEi\/ARB + CCB + thiazide<\/li>\n
    • Cirrhotic ascites<\/strong> — first-line diuretic in cirrhosis (loop diuretics added if response inadequate)<\/li>\n
    • Hirsutism, PCOS-related acne, female-pattern hair loss<\/strong> — off-label anti-androgen therapy<\/li>\n
    • Post-MI with LV dysfunction<\/strong> — eplerenone is preferred (EPHESUS trial specific)<\/li>\n<\/ul>\n

      Viktiga kliniska studier:<\/strong> RALES (1999)<\/strong> — landmark trial of spironolactone 25-50 mg in severe HF-REF; 30% reduction in all-cause mortality. Established aldosterone antagonism as standard HF-REF therapy. EPHESUS<\/strong> och EMPHASIS-HF<\/strong> extended to eplerenone. PATHWAY-2 (2015)<\/strong> — spironolactone 25-50 mg was the most effective fourth agent for resistant hypertension vs bisoprolol or doxazosin. TOPCAT<\/strong> — modest benefit in HF with preserved ejection fraction (HF-PEF); signal stronger in Americas arm than Russia arm (controversial).<\/p>\n

      Silectone Dosage<\/h2>\n

      Heart dose:<\/strong> Resistent hypertoni<\/strong> (BP not controlled on ACEi\/ARB + CCB + thiazide): 25-50 mg once daily — PATHWAY-2 evidence. Spironolactone beats bisoprolol and doxazosin as the fourth agent in resistant HTN. Inte ett f\u00f6rstahandsval vid hypertoni.<\/strong> Primary aldosteronism (Conn’s):<\/strong> 50-400 mg\/day until potassium and BP normalise, then maintenance 25-100 mg.<\/p>\n

      Andra indikationer:<\/strong> Heart failure with reduced ejection fraction (EF ≤35%):<\/strong> 12.5-25 mg once daily; target 25-50 mg if tolerated (RALES trial). Cirrhotic ascites:<\/strong> 50-400 mg\/day, usually with furosemide 20-160 mg (1:2.5 ratio); target 0.5 kg\/day weight loss. Hirsutism \/ PCOS \/ acne (female patients):<\/strong> 50-200 mg\/day — suppresses androgen-driven hair growth and acne over 3-6 months (off-label but well-established).<\/p>\n

      Administrering:<\/strong> en g\u00e5ng dagligen (eller tv\u00e5 g\u00e5nger dagligen f\u00f6r h\u00f6ga doser loopdiuretika vid hj\u00e4rtsvikt), p\u00e5 morgonen. Kv\u00e4llsdosering orsakar nokturi och b\u00f6r undvikas n\u00e4r det \u00e4r m\u00f6jligt. Ta samma tid varje dag. Mat p\u00e5verkar inte absorptionen av dessa diuretika signifikant.<\/p>\n

      \u00d6vervakningsschema:<\/strong><\/p>\n